Journals / European Journal of Therapeutics / 2021 / Cilt: 27 - Sayı: 4

Gaucher Disease and Dental Approaches

Pages
318–326
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this review is to comprehensively point out the general involvement of GD and to illuminate the dentomaxillofacial findings of this disease, leading dentists on possible oral and dental complications that may develop in dental and surgical procedures of the patients with GD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Gaucher disease (GD) is a lysosomal storage disease that results in glucocerebroside accumulation in the lysosomes due to deficiency of the enzyme glucocerebrosidase (GBA).
📊
Key Findings & Data:However, it is most common in Ashkenazi Jews with a rate of 1/13.
💡
Conclusion & Impact:The aim of this review is to comprehensively point out the general involvement of GD and to illuminate the dentomaxillofacial findings of this disease, leading dentists on possible oral and dental complications that may develop in dental and surgical procedures of the patients with GD.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Gaucher disease (GD) is a lysosomal storage disease that results in glucocerebroside accumulation in the lysosomes due to deficiency of the enzyme glucocerebrosidase (GBA). GD, inherited as an autosomal recessive disorder, is a panethnic disease. However, it is most common in Ashkenazi Jews with a rate of 1/13. GD typically presents organomegaly and multiple organ involvement, in which the bone marrow is infiltrated by lipid-laden macrophages. Three clinical types have been identified based on whether neurological involvement of GD is observed. Type I GD is non-neuronopathic and the most common clinical type. The diagnosis of GD is determined by detecting low levels of GBA enzyme in peripheral blood leukocytes. Mutation analysis should be performed in patients with low enzyme levels. Specific treatment of GD includes enzyme replacement therapy (ERT) as a first step and substrate reduction therapy that can be tried in patients who cannot tolerate ERT. Bisphosphonates can be used as supportive therapy in patients with osteoporosis when there is no response to specific therapy. It is extremely important for dentists to be familiar with the maxillofacial abnormalities such as generalized osteopenia, enlarged bone marrow spaces, pseudocystic lesions, cortical thinning, and mental demineralization observed in the patients with GD, as well as multiple organ involvement, and hematological and skeletal involvement of GD. The aim of this review is to comprehensively point out the general involvement of GD and to illuminate the dentomaxillofacial findings of this disease, leading dentists on possible oral and dental complications that may develop in dental and surgical procedures of the patients with GD.

🔖

Cite This Article

CANGER, E. M., BAYRAM, F., AŞANTOĞROL, F., DURSUN, H. (2022). Gaucher Disease and Dental Approaches. European Journal of Therapeutics, Cilt: 27 - Sayı: 4, 318–326. https://ajindex.com/articles/512147

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (6)

  1. Grabowski GA, Zimran A, Ida H. Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG gaucher registry. Am J Hematol. 2015;90:12-18
  2. Cox TM. Gaucher disease: Understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis. 2001;24:107-121. [CrossRef] 3. Gaucher P. De l’epithelioma primitif de la rate. MD The?se, Faculte´ de Me´decine de Paris, 1882
  3. Brill N, Mandlebaum F, Libman E. Primary splenomegaly-Gaucher type. Am J Med Sci. 1905;129:491-503. [CrossRef] 5. Saudubray J-M, Garcia-Cazorla A. Inborn Metabolic Diseases. 6th ed. Berlin, Heidelberg: Springer Berlin Heidelberg, 2016: 3-70
  4. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: Demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000;160(18):2835-2843. [CrossRef] 7. Orcel P, Javier R, Hochberg MC, Gravallese EM. Rheumatology. Philadelphia: Elsevier 2019: 1761-1767
  5. Boot RG, Renkema GH, Verhoek M, et al. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem. 1998;273(40):25680-25685. [CrossRef] 9. Taddei TH, Kacena KA, Yang M, et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol. 2009;84(4):208-214. [CrossRef] 10. Wenger DA, Clark C, Sattler M, Wharton C. Synthetic substrate beta-glucosidase activity in leukocytes: A reproducible method for the identification of patients and carriers of Gaucher’s disease. Clin Genet. 2008;13(2):145-153. [CrossRef] 11. Patterson M, Horowitz M, Abel R, et al. Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher’s disease. Neurology. 1993;43:1993-1997. [CrossRef] 12. Pastores GM, Hughes DA. GeneReviewsVR [Internet]. Seattle: University of Washington, 2018
  6. Zimran A, Altarescu G, Rudensky B, Abrahamov A, Elstein D. Survey of hematological aspects of Gaucher disease. Hematology. 2005;10(2):151-156. [CrossRef] 14. Mohamed YSA, Zayet MK, Omar OM, El-Beshlawy AM. Jaw bones’ involvement and dental features of type I and type III Gaucher disease: A radiographic study of 42 paediatric patients. Eur Arch Paediatr Dent. 2020;21(2):241-247. [CrossRef] 15. Saranjam HR, Sidransky E, Levine WZ, Zimran A, Elstein D. Mandibular and dental manifestations of Gaucher disease. Oral Dis. 2012;18(5):421-429. [CrossRef] 16. Zeevi I, Anavi Y, Kaplan I, Zadik Y. Jaws features in type 1 Gaucher disease. J Oral Ma